Immuron Ltd ADR

Immuron Ltd ADR EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Immuron Ltd ADR (IMRN) as of Nov 8, 2026 is -4.63 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -3.72 M USD — a change of 24.58% (lower).

EBITDA

-4.63 MUSD

YoY

24.58%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Immuron Ltd ADR is 2026 -4.63 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Immuron Ltd ADR was 2025 -3.72 M USD. It decreases by 24.58% lower compared to the previous year.

The Immuron Ltd ADR EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
-3.24 M USD
Jan 1, 2020
-2.03 M USD
Jan 1, 2021
-5.83 M USD
Jan 1, 2022
-2.00 M USD
Jan 1, 2023
-2.48 M USD
Jan 1, 2024
-4.04 M USD
Jan 1, 2025
-3.72 M USD
Jan 1, 2026
-4.63 M USD
The Immuron Ltd ADR EBITDA history
YEAREBITDAYoY
-4.63 MUSD+24.58%
-3.72 MUSD-7.87%
-4.04 MUSD+62.55%
-2.48 MUSD+24.36%
-2.00 MUSD-65.75%
-5.83 MUSD+187.29%
-2.03 MUSD-37.36%
-3.24 MUSD+43.42%
-2.26 MUSD-61.30%
-5.84 MUSD+1.54%
-5.75 MUSD+93.08%
-2.98 MUSD0.00%
-2.98 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Immuron Ltd ADR Stock analysis

What does Immuron Ltd ADR do? Immuron Ltd ADR is a biopharmaceutical company listed on the US market in 2017, operating from Carlton. The firm engages in the research, development, and commercialization of polyclonal antibodies across Australia, the United States, and Canada. It operates through Research and Development and Hyper-immune Products segments. Immuron offers Travelan, an over-the-counter medicine and dietary supplement for digestive health, and Protectyn, an immune supplement. The company also develops clinical-stage candidates, including Travelan (IMM-124E) and IMM-529 for gastrointestinal conditions, alongside the pre-clinical IMM-986. Additionally, Immuron provides a technology platform and maintains collaborations for therapeutic development. Immuron Ltd ADR is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immuron Ltd ADR stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Immuron Ltd ADR is -4.63 M USD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Immuron Ltd ADR changed from -3.72 M USD to -4.63 M USD, representing a 24.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Immuron Ltd ADR since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Immuron Ltd ADR historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Immuron Ltd ADR

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Immuron Ltd ADR